Announced Sun, 15 Mar · 18:38 IST

Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Regulatory & Legal View source PDF

MEDPLUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.6%1-day move
₹841.10
prior close
₹839.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1-1.4-1.1-1.3-2.6+0.4-2.3-2.6-4.9-1.2+2.1+3.2+10.3+3.4
Up moveDown movePending
AI summary

Medplus Health Services Limited informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received a two-day suspension order for the Drug License of its store located at Bidadi Bus Stand in Karnataka. The order was issued by the Assistant Director, Drugs Control Administration, Bangalore South Circle, Ramanagar, under Rule 65 of the Drugs and Cosmetics Act, 1940, and was received on March 14, 2026. The company has disclosed a potential revenue loss of approximately Rs 2.88 lakhs due to this suspension. The disclosure is being made under SEBI's Regulation 30 read with Schedule III.

Likely market impact

The financial impact is negligible at Rs 2.88 lakhs, affecting only a single store for two days, so this is unlikely to have any meaningful effect on the stock price or overall business operations.